Glucagon-like peptide 1 (GLP-1)

T. D. Mueller; B. Finan; S. R. Bloom; D. D'Alessio; D. J. Drucker; P. R. Flatt; A. Fritsche; F. Gribble; H. J. Grill; J. F. Habener; J. J. Holst; W. Langhans; J. J. Meier; M. A. Nauck; D. Perez-Tilve; A. Pocai; F. Reimann; D. A. Sandoval; T. W. Schwartz; R. J. Seeley; K. Stemmer; M. Tang-Christensen; S. C. Woods; R. D. DiMarchi; M. H. Tschoep

doi:10.1016/j.molmet.2019.09.010

Glucagon-like peptide 1 (GLP-1)

T. D. Mueller, B. Finan, S. R. Bloom, D. D'Alessio, D. J. Drucker, P. R. Flatt, A. Fritsche, F. Gribble, H. J. Grill, J. F. Habener, J. J. Holst, W. Langhans, J. J. Meier, M. A. Nauck, D. Perez-Tilve, A. Pocai, F. Reimann, D. A. Sandoval, T. W. Schwartz, R. J. SeeleyK. Stemmer, M. Tang-Christensen, S. C. Woods, R. D. DiMarchi, M. H. Tschoep

Endocrinology and Metabolism

166 Citationer (Scopus)

Abstract

Background: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of food intake, increase of natriuresis and diuresis, and modulation of rodent beta-cell proliferation. GLP-1 also has cardio- and neuroprotective effects, decreases inflammation and apoptosis, and has implications for learning and memory, reward behavior, and palatability. Biochemically modified for enhanced potency and sustained action, GLP-1 receptor agonists are successfully in clinical use for the treatment of type-2 diabetes, and several GLP-1-based pharmacotherapies are in clinical evaluation for the treatment of obesity.

Scope of review: In this review, we provide a detailed overview on the multifaceted nature of GLP-1 and its pharmacology and discuss its therapeutic implications on various diseases.

Major conclusions: Since its discovery, GLP-1 has emerged as a pleiotropic hormone with a myriad of metabolic functions that go well beyond its classical identification as an incretin hormone. The numerous beneficial effects of GLP-1 render this hormone an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, and neurodegenerative disorders (C) 2019 The Authors. Published by Elsevier GmbH.

Originalsprog	Engelsk
Tidsskrift	Molecular Metabolism
Vol/bind	30
Sider (fra-til)	72-130
ISSN	2212-8778
DOI	https://doi.org/10.1016/j.molmet.2019.09.010
Status	Udgivet - dec. 2019

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1016/j.molmet.2019.09.010Licens: CC BY-NC-ND

OA-Glucagon-like peptide 1 (GLP-1)Forlagets udgivne version, 3,93 MBLicens: CC BY-NC-ND

Citationsformater

Mueller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., Holst, J. J., Langhans, W., Meier, J. J., Nauck, M. A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D. A., Schwartz, T. W., ... Tschoep, M. H. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72-130. https://doi.org/10.1016/j.molmet.2019.09.010

Mueller, TD, Finan, B, Bloom, SR, D'Alessio, D, Drucker, DJ, Flatt, PR, Fritsche, A, Gribble, F, Grill, HJ, Habener, JF, Holst, JJ, Langhans, W, Meier, JJ, Nauck, MA, Perez-Tilve, D, Pocai, A, Reimann, F, Sandoval, DA, Schwartz, TW, Seeley, RJ, Stemmer, K, Tang-Christensen, M, Woods, SC, DiMarchi, RD & Tschoep, MH 2019, 'Glucagon-like peptide 1 (GLP-1)', Molecular Metabolism, bind 30, s. 72-130. https://doi.org/10.1016/j.molmet.2019.09.010

@article{c564517f4564472192caa221d3bc16c1,

title = "Glucagon-like peptide 1 (GLP-1)",

abstract = "Background: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of food intake, increase of natriuresis and diuresis, and modulation of rodent β-cell proliferation. GLP-1 also has cardio- and neuroprotective effects, decreases inflammation and apoptosis, and has implications for learning and memory, reward behavior, and palatability. Biochemically modified for enhanced potency and sustained action, GLP-1 receptor agonists are successfully in clinical use for the treatment of type-2 diabetes, and several GLP-1-based pharmacotherapies are in clinical evaluation for the treatment of obesity. Scope of review: In this review, we provide a detailed overview on the multifaceted nature of GLP-1 and its pharmacology and discuss its therapeutic implications on various diseases. Major conclusions: Since its discovery, GLP-1 has emerged as a pleiotropic hormone with a myriad of metabolic functions that go well beyond its classical identification as an incretin hormone.",

keywords = "GLP-1, Insulin, Glucagon, Diabetes, Obesity",

author = "Mueller, {T. D.} and B. Finan and Bloom, {S. R.} and D. D'Alessio and Drucker, {D. J.} and Flatt, {P. R.} and A. Fritsche and F. Gribble and Grill, {H. J.} and Habener, {J. F.} and Holst, {J. J.} and W. Langhans and Meier, {J. J.} and Nauck, {M. A.} and D. Perez-Tilve and A. Pocai and F. Reimann and Sandoval, {D. A.} and Schwartz, {T. W.} and Seeley, {R. J.} and K. Stemmer and M. Tang-Christensen and Woods, {S. C.} and DiMarchi, {R. D.} and Tschoep, {M. H.}",

year = "2019",

month = dec,

doi = "10.1016/j.molmet.2019.09.010",

language = "English",

volume = "30",

pages = "72--130",

journal = "Molecular Metabolism",

issn = "2212-8778",

publisher = "Elsevier",

}

TY - JOUR

T1 - Glucagon-like peptide 1 (GLP-1)

AU - Mueller, T. D.

AU - Finan, B.

AU - Bloom, S. R.

AU - D'Alessio, D.

AU - Drucker, D. J.

AU - Flatt, P. R.

AU - Fritsche, A.

AU - Gribble, F.

AU - Grill, H. J.

AU - Habener, J. F.

AU - Holst, J. J.

AU - Langhans, W.

AU - Meier, J. J.

AU - Nauck, M. A.

AU - Perez-Tilve, D.

AU - Pocai, A.

AU - Reimann, F.

AU - Sandoval, D. A.

AU - Schwartz, T. W.

AU - Seeley, R. J.

AU - Stemmer, K.

AU - Tang-Christensen, M.

AU - Woods, S. C.

AU - DiMarchi, R. D.

AU - Tschoep, M. H.

PY - 2019/12

Y1 - 2019/12

N2 - Background: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of food intake, increase of natriuresis and diuresis, and modulation of rodent β-cell proliferation. GLP-1 also has cardio- and neuroprotective effects, decreases inflammation and apoptosis, and has implications for learning and memory, reward behavior, and palatability. Biochemically modified for enhanced potency and sustained action, GLP-1 receptor agonists are successfully in clinical use for the treatment of type-2 diabetes, and several GLP-1-based pharmacotherapies are in clinical evaluation for the treatment of obesity. Scope of review: In this review, we provide a detailed overview on the multifaceted nature of GLP-1 and its pharmacology and discuss its therapeutic implications on various diseases. Major conclusions: Since its discovery, GLP-1 has emerged as a pleiotropic hormone with a myriad of metabolic functions that go well beyond its classical identification as an incretin hormone.

AB - Background: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of food intake, increase of natriuresis and diuresis, and modulation of rodent β-cell proliferation. GLP-1 also has cardio- and neuroprotective effects, decreases inflammation and apoptosis, and has implications for learning and memory, reward behavior, and palatability. Biochemically modified for enhanced potency and sustained action, GLP-1 receptor agonists are successfully in clinical use for the treatment of type-2 diabetes, and several GLP-1-based pharmacotherapies are in clinical evaluation for the treatment of obesity. Scope of review: In this review, we provide a detailed overview on the multifaceted nature of GLP-1 and its pharmacology and discuss its therapeutic implications on various diseases. Major conclusions: Since its discovery, GLP-1 has emerged as a pleiotropic hormone with a myriad of metabolic functions that go well beyond its classical identification as an incretin hormone.

KW - GLP-1

KW - Insulin

KW - Glucagon

KW - Diabetes

KW - Obesity

U2 - 10.1016/j.molmet.2019.09.010

DO - 10.1016/j.molmet.2019.09.010

M3 - Review

C2 - 31767182

SN - 2212-8778

VL - 30

SP - 72

EP - 130

JO - Molecular Metabolism

JF - Molecular Metabolism

ER -

Glucagon-like peptide 1 (GLP-1)

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater